Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Placental development and physiology

INTRODUCTION

Development of the placenta is a highly regulated process that is essential for normal fetal growth and development, and for maintenance of a healthy pregnancy. The placenta fulfills several critical roles as the interface between mother and fetus: it prevents rejection of the fetal allograft, enables respiratory gas exchange, transports nutrients, eliminates fetal waste products, and secretes peptide and steroid hormones.

EARLY DEVELOPMENT

Implantation and invasion — Development of the placenta and fetus is a continuous process that begins at the time of fertilization. The first three days of development occur within the fallopian tube. Four days after fertilization, the morula (a solid mass of blastomere cells) enters the uterus. On the fifth day after fertilization, the morula becomes a blastocyst as fluid accumulates and polarization of the cells occurs. The blastocyst has an outer layer of cells (trophoblast) that will form the placenta and fetal membranes, an inner cell mass at one pole that will form the embryo, and a fluid filled cavity. The inner and outer cell masses multiply and the fluid cavity enlarges until the expanded blastocyst hatches out of the zona shell. Initially it is bathed in uterine secretions that provide oxygen and metabolic substrates; however, these secretions soon become inadequate for support of further development. Therefore, within 24 hours of hatching (about day 6 after fertilization), the blastocyst implants in the uterine lining, which provides access to substrates (glycogen filled stromal cells) necessary for continued growth. Implantation involves movement of the blastocyst to an optimal location (typically the mid to upper anterior or posterior wall of the uterus), adhesion, and invasion. As the trophoblast erodes deeper into the decidua, vacuoles form and become confluent to form lacunae by day 13 after fertilization. The lacunar space eventually becomes the intervillous space.

The progenitor cytotrophoblast cell is the stem cell of the placenta. These cells proliferate throughout gestation, differentiating along two pathways to form either villous cytotrophoblast which ultimately can become syncytiotrophoblasts (outer cellular layer) or extravillous cytotrophoblasts (inner cellular layer) (algorithm 1). Syncytiotrophoblast is a specialized epithelium that has several functions, including transport of gases, nutrients, and waste products and synthesis of peptide and steroid hormones that regulate placental, fetal, and maternal systems. Extravillous trophoblast (EVT) has a proliferative component and an invasive component. There is also a migratory EVT, which is neither invasive nor proliferative. These cells populate the cell islands, septum, chorionic plate and chorion laeve.

At four to five weeks of gestation (menstrual dates), EVT erupts in columns with proliferative trophoblast at the base and invasive trophoblast at the distal portion of the column. Invasive EVT that invades decidua is called interstitial EVT, whereas EVT that invades and remodels the spiral arteries is called endovascular EVT. Endovascular invasion (intramural or intra-arterial) involves replacement or displacement of vascular smooth muscle and endothelial cells and transforms the narrow spiral arteries into wide uteroplacental arteries (algorithm 1). Anastomoses between the dilated spiral arteries and endometrial veins form maternal sinusoids, which eventually distribute blood into the low resistance vascular network of the lacunar system, thus establishing the uteroplacental circulation.

During invasion, EVT expresses specific proteins defining the stage and role in the differentiation and invasion process. These include integrin cell-extracellular matrix antigens, matrix metalloproteinases (MMPs), signal transduction proteins such as transforming growth factor-ß (TGF-ß), vascular endothelial growth factor (VEGF) and VEGF receptors, and insulin-like growth factor 2 (IGF2).

                             

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jul 2014. | This topic last updated: Dec 18, 2013.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Hustin J, Schaaps JP. Echographic [corrected] and anatomic studies of the maternotrophoblastic border during the first trimester of pregnancy. Am J Obstet Gynecol 1987; 157:162.
  2. Burton GJ, Hempstock J, Jauniaux E. Nutrition of the human fetus during the first trimester--a review. Placenta 2001; 22 Suppl A:S70.
  3. Burton GJ, Hempstock J, Jauniaux E. Oxygen, early embryonic metabolism and free radical-mediated embryopathies. Reprod Biomed Online 2003; 6:84.
  4. Burton GJ, Jauniaux E. Placental oxidative stress: from miscarriage to preeclampsia. J Soc Gynecol Investig 2004; 11:342.
  5. Jauniaux E, Watson AL, Hempstock J, et al. Onset of maternal arterial blood flow and placental oxidative stress. A possible factor in human early pregnancy failure. Am J Pathol 2000; 157:2111.
  6. Burton GJ, Jauniaux E. Oxidative stress. Best Pract Res Clin Obstet Gynaecol 2011; 25:287.
  7. Caniggia I, Winter J, Lye SJ, Post M. Oxygen and placental development during the first trimester: implications for the pathophysiology of pre-eclampsia. Placenta 2000; 21 Suppl A:S25.
  8. Mi S, Lee X, Li X, et al. Syncytin is a captive retroviral envelope protein involved in human placental morphogenesis. Nature 2000; 403:785.
  9. Lee X, Keith JC Jr, Stumm N, et al. Downregulation of placental syncytin expression and abnormal protein localization in pre-eclampsia. Placenta 2001; 22:808.
  10. Knerr I, Beinder E, Rascher W. Syncytin, a novel human endogenous retroviral gene in human placenta: evidence for its dysregulation in preeclampsia and HELLP syndrome. Am J Obstet Gynecol 2002; 186:210.
  11. Charnock-Jones DS, Burton GJ. Placental vascular morphogenesis. Baillieres Best Pract Res Clin Obstet Gynaecol 2000; 14:953.
  12. Flint Porter T, Silver RM, Ware Branch, D. Pregnancy loss and antiphospholipid antibodies. In: Hughes Syndrome Antiphospholipid Syndrome, Khamashta MA (Ed), Springer-Verlag, London 2000. p.179.
  13. Myatt L. Role of placenta in preeclampsia. Endocrine 2002; 19:103.
  14. Krikun G, Lockwood CJ, Wu XX, et al. The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: immunolocalization and in vitro regulation. Placenta 1994; 15:601.
  15. Rand JH, Wu XX, Andree HA, et al. Pregnancy loss in the antiphospholipid-antibody syndrome--a possible thrombogenic mechanism. N Engl J Med 1997; 337:154.
  16. Reik W, Constância M, Fowden A, et al. Regulation of supply and demand for maternal nutrients in mammals by imprinted genes. J Physiol 2003; 547:35.
  17. Koukoura O, Sifakis S, Zaravinos A, et al. Hypomethylation along with increased H19 expression in placentas from pregnancies complicated with fetal growth restriction. Placenta 2011; 32:51.
  18. Fowden AL, Coan PM, Angiolini E, et al. Imprinted genes and the epigenetic regulation of placental phenotype. Prog Biophys Mol Biol 2011; 106:281.
  19. Nelissen EC, van Montfoort AP, Dumoulin JC, Evers JL. Epigenetics and the placenta. Hum Reprod Update 2011; 17:397.
  20. Caniggia I, Grisaru-Gravnosky S, Kuliszewsky M, et al. Inhibition of TGF-beta 3 restores the invasive capability of extravillous trophoblasts in preeclamptic pregnancies. J Clin Invest 1999; 103:1641.
  21. Dokras A, Gardner LM, Seftor EA, Hendrix MJ. Regulation of human cytotrophoblast morphogenesis by hepatocyte growth factor/scatter factor. Biol Reprod 2001; 65:1278.
  22. Ishihara N, Matsuo H, Murakoshi H, et al. Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by either preeclampsia or intrauterine growth retardation. Am J Obstet Gynecol 2002; 186:158.
  23. Leung DN, Smith SC, To KF, et al. Increased placental apoptosis in pregnancies complicated by preeclampsia. Am J Obstet Gynecol 2001; 184:1249.
  24. Tantbirojn P, Crum CP, Parast MM. Pathophysiology of placenta creta: the role of decidua and extravillous trophoblast. Placenta 2008; 29:639.
  25. Khong TY. The pathology of placenta accreta, a worldwide epidemic. J Clin Pathol 2008; 61:1243.
  26. Hahn D, Blaschitz A, Korgun ET, et al. From maternal glucose to fetal glycogen: expression of key regulators in the human placenta. Mol Hum Reprod 2001; 7:1173.
  27. Herrera E, Amusquivar E, López-Soldado I, Ortega H. Maternal lipid metabolism and placental lipid transfer. Horm Res 2006; 65 Suppl 3:59.
  28. Beaconsfield P, Birdwood G, Beaconsfield R. The placenta. Sci Am 1980; 243:94.
  29. Settle P, Mynett K, Speake P, et al. Polarized lactate transporter activity and expression in the syncytiotrophoblast of the term human placenta. Placenta 2004; 25:496.
  30. Randhawa R, Cohen P. The role of the insulin-like growth factor system in prenatal growth. Mol Genet Metab 2005; 86:84.
  31. Clifton VL, Read MA, Leitch IM, et al. Corticotropin-releasing hormone-induced vasodilatation in the human fetal placental circulation. J Clin Endocrinol Metab 1994; 79:666.
  32. Clifton VL, Read MA, Leitch IM, et al. Corticotropin-releasing hormone-induced vasodilatation in the human fetal-placental circulation: involvement of the nitric oxide-cyclic guanosine 3',5'-monophosphate-mediated pathway. J Clin Endocrinol Metab 1995; 80:2888.
  33. Charnock-Jones DS, Sharkey AM, Boocock CA, et al. Vascular endothelial growth factor receptor localization and activation in human trophoblast and choriocarcinoma cells. Biol Reprod 1994; 51:524.
  34. Shore VH, Wang TH, Wang CL, et al. Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast. Placenta 1997; 18:657.
  35. Toriola AT, Vääräsmäki M, Lehtinen M, et al. Determinants of maternal sex steroids during the first half of pregnancy. Obstet Gynecol 2011; 118:1029.
  36. Siiteri PK. The continuing saga of dehydroepiandrosterone (DHEA). J Clin Endocrinol Metab 2005; 90:3795.
  37. Murphy VE, Clifton VL. Alterations in human placental 11beta-hydroxysteroid dehydrogenase type 1 and 2 with gestational age and labour. Placenta 2003; 24:739.
  38. Alfaidy N, Gupta S, DeMarco C, et al. Oxygen regulation of placental 11 beta-hydroxysteroid dehydrogenase 2: physiological and pathological implications. J Clin Endocrinol Metab 2002; 87:4797.
  39. Pepe GJ, Burch MG, Albrecht ED. Localization and developmental regulation of 11beta-hydroxysteroid dehydrogenase-1 and -2 in the baboon syncytiotrophoblast. Endocrinology 2001; 142:68.
  40. Brownbill P, Mahendran D, Owen D, et al. Denudations as paracellular routes for alphafetoprotein and creatinine across the human syncytiotrophoblast. Am J Physiol Regul Integr Comp Physiol 2000; 278:R677.
  41. Sibley CP, Boyd RDH. Mechanisms of transfer across the human placenta. In: Fetal and Neonatal physiology, Fox, PA (Eds), WB Saunders Co, Philadelphia 2004. p.111.
  42. Liu H, Wintour EM. Aquaporins in development -- a review. Reprod Biol Endocrinol 2005; 3:18.
  43. Johansson M, Jansson T, Powell TL. Na(+)-K(+)-ATPase is distributed to microvillous and basal membrane of the syncytiotrophoblast in human placenta. Am J Physiol Regul Integr Comp Physiol 2000; 279:R287.
  44. Strid H, Powell TL. ATP-dependent Ca2+ transport is up-regulated during third trimester in human syncytiotrophoblast basal membranes. Pediatr Res 2000; 48:58.
  45. Carter AM. Factors affecting gas transfer across the placenta and the oxygen supply to the fetus. J Dev Physiol 1989; 12:305.
  46. Leonce J, Brockton N, Robinson S, et al. Glucose production in the human placenta. Placenta 2006; 27 Suppl A:S103.
  47. Illsley NP. Glucose transporters in the human placenta. Placenta 2000; 21:14.
  48. Regnault TR, de Vrijer B, Battaglia FC. Transport and metabolism of amino acids in placenta. Endocrine 2002; 19:23.
  49. Jansson T, Powell TL. Placental nutrient transfer and fetal growth. Nutrition 2000; 16:500.
  50. Regnault TR, Marconi AM, Smith CH, et al. Placental amino acid transport systems and fetal growth restriction--a workshop report. Placenta 2005; 26 Suppl A:S76.
  51. Galan HL, Marconi AM, Paolini CL, et al. The transplacental transport of essential amino acids in uncomplicated human pregnancies. Am J Obstet Gynecol 2009; 200:91.e1.
  52. Ronzoni S, Marconi AM, Paolini CL, et al. The effect of a maternal infusion of amino acids on umbilical uptake in pregnancies complicated by intrauterine growth restriction. Am J Obstet Gynecol 2002; 187:741.
  53. Simister NE. Placental transport of immunoglobulin G. Vaccine 2003; 21:3365.
  54. Marin JJ, Briz O, Serrano MA. A review on the molecular mechanisms involved in the placental barrier for drugs. Curr Drug Deliv 2004; 1:275.
  55. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 2004; 43:487.
  56. Schauberger CW, Pitkin RM. Maternal-perinatal calcium relationships. Obstet Gynecol 1979; 53:74.
  57. Husain SM, Mughal MZ. Mineral transport across the placenta. Arch Dis Child 1992; 67:874.
  58. Belkacemi L, Bédard I, Simoneau L, Lafond J. Calcium channels, transporters and exchangers in placenta: a review. Cell Calcium 2005; 37:1.
  59. Seki K, Wada S, Nagata N, Nagata I. Parathyroid hormone-related protein during pregnancy and the perinatal period. Gynecol Obstet Invest 1994; 37:83.
  60. Farrugia W, Ho PW, Rice GE, et al. Parathyroid hormone-related protein(1-34) in gestational fluids and release from human gestational tissues. J Endocrinol 2000; 165:657.
  61. Strid H, Care A, Jansson T, Powell T. Parathyroid hormone-related peptide (38-94) amide stimulates ATP-dependent calcium transport in the Basal plasma membrane of the human syncytiotrophoblast. J Endocrinol 2002; 175:517.
  62. Philbrick WM, Wysolmerski JJ, Galbraith S, et al. Defining the roles of parathyroid hormone-related protein in normal physiology. Physiol Rev 1996; 76:127.
  63. Tuan RS. Ca2+-binding protein of the human placenta. Characterization, immunohistochemical localization and functional involvement in Ca2+ transport. Biochem J 1985; 227:317.
  64. Belkacemi L, Gariépy G, Mounier C, et al. Calbindin-D9k (CaBP9k) localization and levels of expression in trophoblast cells from human term placenta. Cell Tissue Res 2004; 315:107.
  65. Forbes GB. Letter: Calcium accumulation by the human fetus. Pediatrics 1976; 57:976.
  66. Weisman Y, Harell A, Edelstein S, et al. 1 alpha, 25-Dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 in vitro synthesis by human decidua and placenta. Nature 1979; 281:317.